24H | Moderna Plunges 9% as CEO Announces Curb on Vaccine Trial Investments Due to US Backlash

Stock Track01-23 10:05

Moderna experienced a significant plunge of 8.6% in overnight trading. The decline reflects a shift in investor sentiment following concerning news about the company's future investment strategy.

The drop comes after Moderna's Chief Executive Stephane Bancel stated in an interview with Bloomberg TV that the company does not plan to invest in new late-stage vaccine trials. Bancel cited growing opposition to immunizations from U.S. officials as the primary reason, emphasizing that "you cannot make a return on investment if you don't have access to the US market." This announcement signals potential headwinds for Moderna's traditional vaccine business segment.

Market analysts view this development as particularly significant given the company's recent reliance on its oncology pipeline for growth, as its core respiratory vaccine business faces challenges. The CEO's comments at the World Economic Forum in Davos suggest regulatory delays and reduced government support are constraining the vaccine market size, impacting Moderna's long-term strategic planning.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

2

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155164111?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155164111","market":"us","top_or_hot":-1,"title":"24H | Moderna Plunges 9% as CEO Announces Curb on Vaccine Trial Investments Due to US Backlash","media":"Stock Track","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna</a> experienced a significant plunge of 8.6% in overnight trading. The decline reflects a shift in investor sentiment following concerning news about the company&#39;s future investment strategy.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/c83af5a9e0986b247e1e5474851dbc63\" tg-width=\"536\" tg-height=\"185\"/></p><p>The drop comes after Moderna&#39;s Chief Executive Stephane Bancel stated in an interview with Bloomberg TV that the company does not plan to invest in new late-stage vaccine trials. Bancel cited growing opposition to immunizations from U.S. officials as the primary reason, emphasizing that &#34;you cannot make a return on investment if you don&#39;t have access to the US market.&#34; This announcement signals potential headwinds for Moderna&#39;s traditional vaccine business segment.</p><p>Market analysts view this development as particularly significant given the company&#39;s recent reliance on its oncology pipeline for growth, as its core respiratory vaccine business faces challenges. The CEO&#39;s comments at the World Economic Forum in Davos suggest regulatory delays and reduced government support are constraining the vaccine market size, impacting Moderna&#39;s long-term strategic planning.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>24H | Moderna Plunges 9% as CEO Announces Curb on Vaccine Trial Investments Due to US Backlash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n24H | Moderna Plunges 9% as CEO Announces Curb on Vaccine Trial Investments Due to US Backlash\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-23 10:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna</a> experienced a significant plunge of 8.6% in overnight trading. The decline reflects a shift in investor sentiment following concerning news about the company&#39;s future investment strategy.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/c83af5a9e0986b247e1e5474851dbc63\" tg-width=\"536\" tg-height=\"185\"/></p><p>The drop comes after Moderna&#39;s Chief Executive Stephane Bancel stated in an interview with Bloomberg TV that the company does not plan to invest in new late-stage vaccine trials. Bancel cited growing opposition to immunizations from U.S. officials as the primary reason, emphasizing that &#34;you cannot make a return on investment if you don&#39;t have access to the US market.&#34; This announcement signals potential headwinds for Moderna&#39;s traditional vaccine business segment.</p><p>Market analysts view this development as particularly significant given the company&#39;s recent reliance on its oncology pipeline for growth, as its core respiratory vaccine business faces challenges. The CEO&#39;s comments at the World Economic Forum in Davos suggest regulatory delays and reduced government support are constraining the vaccine market size, impacting Moderna&#39;s long-term strategic planning.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1155164111","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155164111","pubTimestamp":1769133940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"$Moderna(MRNA)$ experienced a significant plunge of 8.6% in overnight trading. The decline reflects a shift in investor sentiment following concerning news about the company's future investment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|Moderna盘后暴跌5.05%CEO宣布因美国反弹限制疫苗试验投资","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna experienced a significant plunge of 8.6% in overnight trading. The decline reflects a shift in investor sentiment following concerning news about the company's future investment strategy.The drop comes after Moderna's Chief Executive Stephane Bancel stated in an interview with Bloomberg TV that the company does not plan to invest in new late-stage vaccine trials. Bancel cited growing opposition to immunizations from U.S. officials as the primary reason, emphasizing that \"you cannot make a return on investment if you don't have access to the US market.\" This announcement signals potential headwinds for Moderna's traditional vaccine business segment.Market analysts view this development as particularly significant given the company's recent reliance on its oncology pipeline for growth, as its core respiratory vaccine business faces challenges. The CEO's comments at the World Economic Forum in Davos suggest regulatory delays and reduced government support are constraining the vaccine market size, impacting Moderna's long-term strategic planning.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155164111","isCrawlerRequest":true}